CIRM awards US$ 4 mn grant to Entos Pharma to advance development of ENTLEP001, a durable and redosable genetic medicine to treat CGL: San Diego Friday, February 7, 2025, 15:00 Hr ...

Few men use the most effective erection drugs because they must be self-injected into the penis. Few men are willing, but ...

French company DNA Script will contribute its enzymatic DNA synthesis technologies, while Quantoom of Belgium will bring its ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

A panel of 14 medical experts say that no babies were murdered in Lucy Letby's care. They have come together to publish what ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Embarking on the quest to lose weight can be a risky business. Yo-yo dieting, compulsive binging, muscle wasting and brain ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...

What do you know about the endocrine system? In school, we learned that hormones and the glands that produce them comprise ...